(EXLS) ExlService Holdings - Ratings and Ratios
Analytics, Operations, Insurance, Healthcare, Banking
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 27.6% |
| Value at Risk 5%th | 40.3% |
| Relative Tail Risk | -11.27% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.54 |
| Alpha | -25.44 |
| CAGR/Max DD | 0.15 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.279 |
| Beta | 0.757 |
| Beta Downside | 0.838 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.28% |
| Mean DD | 11.77% |
| Median DD | 13.05% |
Description: EXLS ExlService Holdings November 05, 2025
ExlService Holdings, Inc. (NASDAQ: EXLS) delivers data-analytics-driven digital operations and automation solutions across four primary segments: Insurance; Healthcare & Life Sciences; Banking, Capital Markets & Diversified Industries; and International Growth Markets. Its service portfolio spans end-to-end claim processing, underwriting support, premium administration, sub-rogation platforms (Subrosource), and SaaS-based customer acquisition tools (LifePRO, Life Digital Suite), leveraging AI, machine-learning, and advanced automation.
In FY 2023 the company reported revenue of roughly $1.2 billion, representing a 5 % year-over-year increase, while operating margin hovered near 6 %. Growth is being propelled by rising demand for cost-containment solutions in insurance and healthcare-sectors that are grappling with higher claim volumes and regulatory pressure to improve payment integrity. Additionally, the broader data-processing outsourcing market is expanding at a 7-8 % CAGR, driven by enterprises’ accelerated digital transformation initiatives.
Exl’s strategic focus on predictive and prescriptive analytics for customer acquisition and lifecycle management positions it to capture upside from the ongoing shift toward AI-enabled operational efficiency across its core verticals. For a deeper dive into EXLS’s valuation metrics and peer comparisons, you might find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (241.4m TTM) > 0 and > 6% of Revenue (6% = 121.6m TTM) |
| FCFTA 0.17 (>2.0%) and ΔFCFTA 4.48pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 28.60% (prev 28.76%; Δ -0.16pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.20 (>3.0%) and CFO 338.7m > Net Income 241.4m (YES >=105%, WARN >=100%) |
| Net Debt (262.8m) to EBITDA (417.7m) ratio: 0.63 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.89 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (161.7m) change vs 12m ago -0.90% (target <= -2.0% for YES) |
| Gross Margin 38.24% (prev 37.24%; Δ 1.00pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 121.2% (prev 110.0%; Δ 11.21pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 17.80 (EBITDA TTM 417.7m / Interest Expense TTM 18.5m) >= 6 (WARN >= 3) |
Altman Z'' 8.04
| (A) 0.33 = (Total Current Assets 886.6m - Total Current Liabilities 307.0m) / Total Assets 1.73b |
| (B) 0.85 = Retained Earnings (Balance) 1.47b / Total Assets 1.73b |
| warn (B) unusual magnitude: 0.85 — check mapping/units |
| (C) 0.20 = EBIT TTM 328.6m / Avg Total Assets 1.67b |
| (D) 1.67 = Book Value of Equity 1.30b / Total Liabilities 781.2m |
| Total Rating: 8.04 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 85.29
| 1. Piotroski 8.50pt |
| 2. FCF Yield 4.41% |
| 3. FCF Margin 14.16% |
| 4. Debt/Equity 0.46 |
| 5. Debt/Ebitda 0.63 |
| 6. ROIC - WACC (= 11.54)% |
| 7. RoE 24.42% |
| 8. Rev. Trend 98.41% |
| 9. EPS Trend -9.45% |
What is the price of EXLS shares?
Over the past week, the price has changed by +0.73%, over one month by +1.09%, over three months by -9.20% and over the past year by -13.08%.
Is EXLS a buy, sell or hold?
- Strong Buy: 5
- Buy: 3
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the EXLS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 52.3 | 30.5% |
| Analysts Target Price | 52.3 | 30.5% |
| ValueRay Target Price | 37.8 | -5.5% |
EXLS Fundamental Data Overview December 03, 2025
P/E Trailing = 27.0608
P/E Forward = 18.0505
P/S = 3.192
P/B = 6.6204
P/EG = 1.2039
Beta = 0.91
Revenue TTM = 2.03b USD
EBIT TTM = 328.6m USD
EBITDA TTM = 417.7m USD
Long Term Debt = 349.9m USD (from longTermDebt, last quarter)
Short Term Debt = 24.1m USD (from shortTermDebt, last quarter)
Debt = 434.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 262.8m USD (from netDebt column, last quarter)
Enterprise Value = 6.50b USD (6.47b + Debt 434.5m - CCE 401.5m)
Interest Coverage Ratio = 17.80 (Ebit TTM 328.6m / Interest Expense TTM 18.5m)
FCF Yield = 4.41% (FCF TTM 286.9m / Enterprise Value 6.50b)
FCF Margin = 14.16% (FCF TTM 286.9m / Revenue TTM 2.03b)
Net Margin = 11.91% (Net Income TTM 241.4m / Revenue TTM 2.03b)
Gross Margin = 38.24% ((Revenue TTM 2.03b - Cost of Revenue TTM 1.25b) / Revenue TTM)
Gross Margin QoQ = 38.51% (prev 37.75%)
Tobins Q-Ratio = 3.75 (Enterprise Value 6.50b / Total Assets 1.73b)
Interest Expense / Debt = 1.13% (Interest Expense 4.92m / Debt 434.5m)
Taxrate = 22.03% (16.5m / 74.7m)
NOPAT = 256.2m (EBIT 328.6m * (1 - 22.03%))
Current Ratio = 2.89 (Total Current Assets 886.6m / Total Current Liabilities 307.0m)
Debt / Equity = 0.46 (Debt 434.5m / totalStockholderEquity, last quarter 952.4m)
Debt / EBITDA = 0.63 (Net Debt 262.8m / EBITDA 417.7m)
Debt / FCF = 0.92 (Net Debt 262.8m / FCF TTM 286.9m)
Total Stockholder Equity = 988.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.93% (Net Income 241.4m / Total Assets 1.73b)
RoE = 24.42% (Net Income TTM 241.4m / Total Stockholder Equity 988.8m)
RoCE = 24.55% (EBIT 328.6m / Capital Employed (Equity 988.8m + L.T.Debt 349.9m))
RoIC = 19.84% (NOPAT 256.2m / Invested Capital 1.29b)
WACC = 8.30% (E(6.47b)/V(6.90b) * Re(8.80%) + D(434.5m)/V(6.90b) * Rd(1.13%) * (1-Tc(0.22)))
Discount Rate = 8.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.56%
[DCF Debug] Terminal Value 79.02% ; FCFE base≈249.9m ; Y1≈308.2m ; Y5≈525.9m
Fair Price DCF = 48.85 (DCF Value 7.75b / Shares Outstanding 158.7m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -9.45 | EPS CAGR: -21.85% | SUE: 1.27 | # QB: 5
Revenue Correlation: 98.41 | Revenue CAGR: 16.83% | SUE: 2.44 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.53 | Chg30d=+0.005 | Revisions Net=+2 | Analysts=6
EPS next Year (2026-12-31): EPS=2.19 | Chg30d=+0.032 | Revisions Net=+8 | Growth EPS=+14.3% | Growth Revenue=+11.3%
Additional Sources for EXLS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle